Bonesupport Holding Croissance future
Future contrôle des critères 6/6
Bonesupport Holding devrait augmenter ses bénéfices et son chiffre d'affaires de 34.5% et de 23.7% par an respectivement. Le BPA devrait croître de de 46.6% par an. Le rendement des capitaux propres devrait être 35.9% dans 3 ans.
Informations clés
34.5%
Taux de croissance des bénéfices
46.56%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 33.4% |
| Taux de croissance des recettes | 23.7% |
| Rendement futur des capitaux propres | 35.93% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 20 May 2026 |
Mises à jour récentes de la croissance future
Article d’analyse • Apr 25
Bonesupport Holding AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models
Bonesupport Holding AB (publ) ( STO:BONEX ) missed earnings with its latest first-quarter results, disappointing...Article d’analyse • Oct 28
Bonesupport Holding AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models
It's shaping up to be a tough period for Bonesupport Holding AB (publ) ( STO:BONEX ), which a week ago released some...Recent updates
Mise à jour du récit • May 13
BONEX: Infection Study Outcomes And Segment Focus Will Drive Future Upside
Analysts have kept their SEK price target for Bonesupport Holding broadly steady, with only minor model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions guiding this latest narrative update. What's in the News Bonesupport Holding plans an analyst and investor day focused on how its segment based approach is intended to increase penetration and market share for CERAMENT in prioritized indication areas.Article d’analyse • Apr 25
Bonesupport Holding AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models
Bonesupport Holding AB (publ) ( STO:BONEX ) missed earnings with its latest first-quarter results, disappointing...Mise à jour du récit • Apr 23
BONEX: Clinical Pilot Infection Outcomes Will Support Future Upside Potential
Analysts have raised their price target for Bonesupport Holding by about SEK 10.60 to SEK 377.17, citing updated assumptions that include a slightly higher discount rate, adjusted revenue growth expectations, a revised profit margin outlook, and a lower future P/E multiple. What's in the News Bonesupport Holding announced the first publication of a US clinical pilot study on the surgical technique and outcomes of CERAMENT G in trauma.Mise à jour du récit • Apr 07
BONEX: Clinical Pilot Outcomes And 2026 Sales Outlook Will Support Future Upside Potential
Analysts have revised their price target on Bonesupport Holding to SEK 366.6. The update reflects an unchanged fair value along with adjusted assumptions for the discount rate, revenue growth, profit margin and future P/E. What's in the News Publication of a US clinical pilot study in OTA International highlighting surgical technique and outcomes for CERAMENT G in trauma cases, providing practical, real world guidance for clinicians considering the product in fracture related infections and osteomyelitis (Key Developments).Mise à jour du récit • Mar 24
BONEX: Clinical Pilot Outcomes And 2025 Guidance Will Support Future Upside Potential
Analysts have kept their SEK price target for Bonesupport Holding unchanged at SEK 366.60, citing broadly consistent assumptions on discount rate, revenue growth, profit margin and future P/E. Together, these factors support a steady valuation view.
Nouveau récit • Mar 12
Slow Trauma Center Adoption And Regulatory Hurdles Will Eventually Support A Healthier Business Mix
Catalysts About Bonesupport Holding Bonesupport Holding develops and sells CERAMENT bone void fillers, including antibiotic eluting products used to treat complex bone infections and defects. What are the underlying business or industry changes driving this perspective?Mise à jour du récit • Mar 10
BONEX: Clinical Pilot Results And Strong Guidance Will Support Long-Term Upside Potential
Analysts have trimmed their price target on Bonesupport Holding by SEK 4 to SEK 366.6. This reflects updated assumptions around discount rates, revenue growth and profitability, while keeping future P/E expectations broadly in line with previous views. What's in the News Bonesupport announced the first publication of a US clinical pilot study on the surgical technique and outcomes of CERAMENT G in trauma, giving clinicians practical, real world insights into its use in trauma cases.
Nouveau récit • Feb 25
US Trauma Expansion And New Surgical Uses Will Transform This Bone Regeneration Specialist
Catalysts About Bonesupport Holding Bonesupport Holding develops and sells CERAMENT bone void fillers, including antibiotic eluting products such as CERAMENT G and CERAMENT V, for use in complex bone infections and orthopedic procedures. What are the underlying business or industry changes driving this perspective?Mise à jour du récit • Feb 23
BONEX: De Novo Shift Will Support Long Term Upside Potential
Analysts have slightly trimmed their fair value estimate for Bonesupport Holding to SEK370.6, from SEK374.6, reflecting minor adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions, while keeping the overall thesis broadly intact. What's in the News Bonesupport issued earnings guidance for Q4 2025, with net sales expected at 313 MSEK at constant exchange rates, based on company guidance for that period (company guidance).Article d’analyse • Feb 12
Is There An Opportunity With Bonesupport Holding AB (publ)'s (STO:BONEX) 43% Undervaluation?
Key Insights Bonesupport Holding's estimated fair value is kr293 based on 2 Stage Free Cash Flow to Equity Current...Mise à jour du récit • Feb 08
BONEX: De Novo Pathway Shift Will Support Long Term Upside Potential
Analysts have kept their fair value estimate for Bonesupport Holding steady at SEK374.60 per share. The latest price target update mainly reflects small technical tweaks to the discount rate and future P/E assumptions rather than a shift in the core outlook.Mise à jour du récit • Jan 22
BONEX: De Novo Review Shift Will Support Long Term Upside Potential
Analysts have trimmed their price target for Bonesupport Holding to SEK 374.60 from SEK 391.20, citing slightly lower assumptions for revenue growth and profit margins, along with a higher future P/E multiple. What's in the News Bonesupport Holding issued earnings guidance for the fourth quarter of 2025 with net sales expected at SEK 313 M, based on constant exchange rates (Corporate guidance).Mise à jour du récit • Jan 07
BONEX: De Novo Pathway Shift Will Support Long Term Upside Potential
Analysts have kept their fair value estimate for Bonesupport Holding steady at SEK391.20, with only minor tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions. This suggests their overall view on the company’s long term potential is essentially unchanged.Mise à jour du récit • Dec 24
BONEX: De Novo Pathway Shift Will Support Strong Future Market Position
Analysts have modestly raised their price target on Bonesupport Holding, citing a slightly lower discount rate and improved visibility into sustaining approximately 38 percent revenue growth and robust 31 percent profit margins. Together, these factors support a fair value of SEK 391.20 per share.Mise à jour du récit • Dec 10
BONEX: Hip Infection Study Success Will Drive Stronger Future Clinical And Market Position
Analysts have modestly raised their price target on Bonesupport Holding to SEK 391.2 per share from SEK 391.2 per share, reflecting largely unchanged long term assumptions on the discount rate, revenue growth, profit margins and future valuation multiples. What's in the News Positive top line data from the CeraHip clinical study show that CERAMENT G enabled successful single stage revision surgery for periprosthetic joint infection of the hip, with no re infections reported over 24 months of follow up (Key Developments).Mise à jour du récit • Nov 25
BONEX: Positive Study Results Will Support Improvements In Hip Infection Outcomes
Analysts have adjusted their price target for Bonesupport Holding, maintaining it at SEK 391.20. Recent evaluations indicate steady expectations in light of updated discount rates and continued confidence in the company's growth and profitability outlook.Article d’analyse • Nov 22
Bonesupport Holding AB (publ) (STO:BONEX) May Have Run Too Fast Too Soon With Recent 25% Price Plummet
To the annoyance of some shareholders, Bonesupport Holding AB (publ) ( STO:BONEX ) shares are down a considerable 25...Mise à jour du récit • Nov 07
BONEX: Clinical Study Results Will Drive Long-Term Patient Outcome Improvements
Bonesupport Holding's analyst price target has been updated downward from SEK 401.80 to SEK 391.20, as analysts factor in slightly softer revenue growth forecasts and a higher discount rate. What's in the News Bonesupport announced positive results from a clinical study showing significantly improved patient-reported outcomes for CERAMENT G in single-stage revision surgery for periprosthetic joint infection of the hip (Key Developments).Article d’analyse • Oct 28
Bonesupport Holding AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models
It's shaping up to be a tough period for Bonesupport Holding AB (publ) ( STO:BONEX ), which a week ago released some...Mise à jour du récit • Oct 24
Positive Clinical Results And US Launch Will Drive Future Success
Analysts have revised their price target for Bonesupport Holding from SEK 419.75 to SEK 401.80. This change reflects adjustments to growth and profitability assumptions.Article d’analyse • Aug 25
Bonesupport Holding AB (publ)'s (STO:BONEX) Shares May Have Run Too Fast Too Soon
Bonesupport Holding AB (publ)'s ( STO:BONEX ) price-to-sales (or "P/S") ratio of 18.3x might make it look like a sell...Article d’analyse • Jul 23
Bonesupport Holding's (STO:BONEX) Soft Earnings Are Actually Better Than They Appear
Bonesupport Holding AB (publ)'s ( STO:BONEX ) recent soft profit numbers didn't appear to worry shareholders, as the...Article d’analyse • Jun 28
Bonesupport Holding AB (publ)'s (STO:BONEX) Intrinsic Value Is Potentially 80% Above Its Share Price
Key Insights The projected fair value for Bonesupport Holding is kr508 based on 2 Stage Free Cash Flow to Equity...Article d’analyse • Apr 28
Analyst Estimates: Here's What Brokers Think Of Bonesupport Holding AB (publ) (STO:BONEX) After Its First-Quarter Report
It's been a good week for Bonesupport Holding AB (publ) ( STO:BONEX ) shareholders, because the company has just...
Nouveau récit • Mar 19
CERAMENT G's US Launch And CERAMENT V's FDA Submission Will Expand Global Presence
CERAMENT G's rapid U.S. penetration addresses a significant market need, likely causing notable revenue growth due to its strong clinical backing.Article d’analyse • Mar 01
kr445 - That's What Analysts Think Bonesupport Holding AB (publ) (STO:BONEX) Is Worth After These Results
Shareholders of Bonesupport Holding AB (publ) ( STO:BONEX ) will be pleased this week, given that the stock price is up...Article d’analyse • Oct 31
Earnings Troubles May Signal Larger Issues for Bonesupport Holding (STO:BONEX) Shareholders
The market wasn't impressed with the soft earnings from Bonesupport Holding AB (publ) ( STO:BONEX ) recently. Our...Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2028 | 2,627 | 749 | 611 | 626 | 5 |
| 12/31/2027 | 1,977 | 492 | 382 | 392 | 6 |
| 12/31/2026 | 1,481 | 307 | 283 | 292 | 5 |
| 3/31/2026 | 1,215 | 185 | 244 | 250 | N/A |
| 12/31/2025 | 1,175 | 142 | 216 | 221 | N/A |
| 9/30/2025 | 1,119 | 152 | 235 | 241 | N/A |
| 6/30/2025 | 1,062 | 148 | 207 | 212 | N/A |
| 3/31/2025 | 998 | 122 | 91 | 95 | N/A |
| 12/31/2024 | 899 | 134 | 60 | 66 | N/A |
| 9/30/2024 | 814 | 91 | -3 | 5 | N/A |
| 6/30/2024 | 735 | 289 | -29 | -21 | N/A |
| 3/31/2024 | 656 | 267 | 0 | 7 | N/A |
| 12/31/2023 | 591 | 245 | -24 | -18 | N/A |
| 9/30/2023 | 522 | 214 | -40 | -37 | N/A |
| 6/30/2023 | 448 | -30 | -66 | -63 | N/A |
| 3/31/2023 | 382 | -51 | -51 | -48 | N/A |
| 12/31/2022 | 329 | -68 | -50 | -47 | N/A |
| 9/30/2022 | 287 | -72 | -62 | -58 | N/A |
| 6/30/2022 | 257 | -71 | -72 | -68 | N/A |
| 3/31/2022 | 234 | -82 | -81 | -77 | N/A |
| 12/31/2021 | 213 | -86 | -87 | -83 | N/A |
| 9/30/2021 | 205 | -88 | -90 | -88 | N/A |
| 6/30/2021 | 198 | -96 | -89 | -87 | N/A |
| 3/31/2021 | 182 | -92 | -88 | -86 | N/A |
| 12/31/2020 | 181 | -101 | -103 | -100 | N/A |
| 9/30/2020 | 174 | -115 | -121 | -117 | N/A |
| 6/30/2020 | 165 | -127 | -143 | -139 | N/A |
| 3/31/2020 | 166 | -151 | -155 | -150 | N/A |
| 12/31/2019 | 155 | -161 | N/A | -164 | N/A |
| 9/30/2019 | 132 | -166 | N/A | -176 | N/A |
| 6/30/2019 | 108 | -191 | N/A | -189 | N/A |
| 3/31/2019 | 98 | -182 | N/A | -177 | N/A |
| 12/31/2018 | 97 | -176 | N/A | -172 | N/A |
| 9/30/2018 | 101 | -182 | N/A | -147 | N/A |
| 6/30/2018 | 119 | -146 | N/A | -128 | N/A |
| 3/31/2018 | 128 | -132 | N/A | -112 | N/A |
| 12/31/2017 | 129 | -129 | N/A | -108 | N/A |
| 9/30/2017 | 132 | -112 | N/A | -112 | N/A |
| 6/30/2017 | 126 | -124 | N/A | -106 | N/A |
| 3/31/2017 | 114 | -124 | N/A | -103 | N/A |
| 12/31/2016 | 105 | -110 | N/A | -82 | N/A |
| 12/31/2015 | 62 | -60 | N/A | -65 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de BONEX ( 34.5% par an) est supérieure au taux d'épargne ( 2% ).
Bénéfices vs marché: Les bénéfices de BONEX ( 34.5% par an) devraient croître plus rapidement que le marché Swedish ( 8.8% par an).
Croissance élevée des bénéfices: Les bénéfices de BONEX devraient augmenter de manière significative au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de BONEX ( 23.7% par an) devrait croître plus rapidement que le marché Swedish ( 0.04% par an).
Croissance élevée des revenus: Le chiffre d'affaires de BONEX ( 23.7% par an) devrait croître plus rapidement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de BONEX devrait être élevé dans 3 ans ( 35.9 %)
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/21 05:31 |
| Cours de l'action en fin de journée | 2026/05/21 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Bonesupport Holding AB (publ) est couverte par 8 analystes. 6 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Erik Cassel | Danske Bank |
| Kristofer Liljeberg-Svensson | DNB Carnegie |